spacer
home > epc > autumn 2019 > code of conduct
PUBLICATIONS
European Pharmaceutical Contractor

Code of Conduct





The regulatory world is nervously awaiting the full effects of the EU’s new requirements for medical and in vitro diagnostic device manufacturers that distribute products in EU markets. The retrofitted regulations place a greater emphasis on safety evidence that can be backed by clinical data and are, therefore, expected to have a considerable impact on the clinical research of any medical devices that are intended for EU markets. The coinciding unease triggered by the UK’s plausible ‘no-deal’ Brexit is intensifying anxieties about the regulatory changes and potential ripple effects. The looming deadlines and uncertainties provide ample reason for device organisations to make certain they understand the impending changes and ensure their clinical research data are ready for the revamped EU regulatory landscape.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Patricia Santos-Serrao started her career in the life science industry in 1994 at Schering-Plough in Kenilworth, New Jersey, US, and later joined Boehringer Ingelheim Pharmaceuticals in Ridgefield, California. She took a leading role within both organisations in transitioning business processes, document management, and submission compilation from a paper to electronic system. Patricia is a member of RAPS and has earned her regulatory affairs certification from RAPS and the Regulatory Affairs Certification Board. She is a member of the DIA and the DIA-sponsored TMF Reference Model Working Group.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Launches Partner Program to Team with Clinical Research Organizations (CROs) Committed to Improving Clinical Trials with Patient-Centric Technology

PHILADELPHIA – August 12, 2019: Signant Health (signanthealth.com), a leading provider of technology for clinical research, today launches the Signant Health Partner Program, a significant investment the company is making to enable clinical research organizations (CROs) to better serve sponsors in the areas of Patient Data, Patient Experience, Clinical Supplies, and Endpoint Quality Solutions. By becoming a Signant Partner, CROs will benefit from new commercial and operational advantages that only come with membership.
More info >>

White Papers

Igb Tamper Evident Folding Box

IGB

The easiest, safest and less expensive solution in compliance with what requires Dir. 62/2011/EU, FDA and TGA.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement